| TGA Action ID |
RC-2026-RN-00321-1 |
| Type of Product |
Medicine |
| Product Name/Description |
Bevacizumab (Mvasi) 3mg in Syringe (Bectondickinson) for Ocular Use
Batch Number: BD26021876
Expiry Date: 11/05/2026
ARTG Exempt |
| ARTG Number |
|
| Action Type |
Product Alert |
| Action Level |
Hospital |
| Hazard Classification |
Class III |
| Reason for the Action |
Prior to patient treatment, the treating clinician noticed that the syringe was empty.
This market action does not affect any other compounded batches of Bevacizumab or any other Slade Health products.
Given the nature of the product, this action was undertaken prior to TGA notification (Immediate Market Action as defined within the PRAC). |
| Instructions for Customers/Users |
Customers are to:
- Inspect any remaining inventory of batch BD26021876. Unaffected stock can continue to be used. |
| Action Commencement Date |
4/05/2026 |
| Responsible Entity |
|
| Contact Information |
03 9565 4300 - Slade Health Head Office |